Acumen Pharmaceuticals, Inc. (ABOS)

Price & Market Data

Price: $2.45

Daily Change: -$0.04 / 1.63%

Daily Range: $2.45 - $2.60

Market Cap: $181,291,232

Daily Volume: 396,401

Performance Metrics

1 Week: 9.57%

1 Month: -6.70%

3 Months: -3.92%

6 Months: 66.13%

1 Year: 142.9%

YTD: 20.89%

About Acumen Pharmaceuticals, Inc. (ABOS)

Stay updated on Acumen Pharmaceuticals, Inc. (ABOS). Price: 2.45, daily change: -$0.04 / 1.63%. Market cap: 181,291,232. Performance YTD, 1-week, and 52-week are key.

Company Details

Employees: 61

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Selected stocks

Uxin Limited (UXIN)

Holley Inc. (HLLY)

Filana Therapeutics, Inc. (FLNA)

Great Elm Group, Inc. (GEG)

Matinas Biopharma Holdings, Inc. (MTNB)